DEFENCE THERAPEUTICS A - DTCFF STOCK NEWS

Defence Therapeutics announces its annual general and special meeting of shareholders scheduled for December 12th, 2024, at 10:00 a.m. (Pacific Time) in Vancouver. Shareholders of record as of November 4, 2024, are eligible to vote, with a proxy deadline of December 10th, 2024, at 10:00 a.m. Due to a Canada Post labour strike, shareholders may experience delays in receiving the Information Circular dated November 8, 2024. The company encourages shareholders to access materials electronically via SEDAR+ and vote according to the Circular's instructions.

Defence Therapeutics announces plans to license its proprietary Accum® technology to pharmaceutical companies developing Antibody Drug Conjugates (ADCs). The technology enhances the delivery and efficacy of biologics by overcoming endosomal entrapment, potentially increasing therapeutic potency and reducing dosing requirements. The company aims to generate revenue through licensing while establishing its technology as an industry standard. Additionally, Defence completed a private placement, issuing 50,000 units at $0.50 per unit for proceeds of $25,000, and amended terms for 1,497,780 warrants, reducing their exercise price from $1.75 to $0.75.

Defence Therapeutics has appointed Dr. Maxime Parisotto as Chief Scientific Officer, Director of Science and Business Development. Dr. Parisotto brings over 20 years of experience in biochemistry, drug development, and innovation, holding a PhD focused on breast cancer and metabolism. His background includes postdoctoral fellowships at IGBMC and Université de Montréal, and a senior analyst role at adMare Bioinnovations. He will complete his MBA from Sherbrooke University in April 2025. The company has granted him 100,000 incentive stock options, exercisable at 60 cents per share for three years. The announcement also notes that Dr. Moutih Rafei has left the company.

Defence Therapeutics has closed a non-brokered private placement of unsecured convertible debentures raising CAD$1,476,000. The new debentures bear an 8.0% annual interest rate, mature on November 16, 2025, and are convertible to common shares at $0.60 per share. This offering settles previous debentures from November 2022. The accrued interest of $251,200 from previous debentures was settled through conversion into 440,697 common shares at $0.57 per share. Additionally, 123,000 common shares were issued to a finder as compensation.

Defence Therapeutics announces a new convertible debenture financing offering for CAD$1,570,000 to settle outstanding debt. The new unsecured debentures will bear an 8.0% annual interest rate and mature on November 16, 2025. Debenture holders can convert their principal into common shares at $0.60 per share, potentially resulting in 2,616,666 new common shares. Additionally, approximately $251,200 in accrued interest from previous debentures will be converted into shares at market price. The securities will have a four-month statutory hold period, and the offering requires regulatory approvals.

Defence Therapeutics has appointed Dr. Svetlana Selivanova to its board of directors. Dr. Selivanova is a radiochemist with over 20 years of experience in radiopharmaceutical development and currently serves as Section Head for Radiochemistry and Medical Applications at Canadian Nuclear Laboratories. She holds key positions in professional societies and serves as an expert-consultant for international organizations. The appointment aligns with Defence's strategy to develop radio-immuno-conjugates using their Accum® platform. The company granted her 100,000 incentive stock options, exercisable at 60 cents per share. Dr. Raimar Lobenberg is stepping down from the board.

Defence Therapeutics has received a 30-day extension from the Canadian Securities Exchange for its non-brokered private placement offering. The company previously closed a first tranche of 1,550,000 units at $0.50 per unit, raising $775,000. The upcoming financing will partially fund the development of Defence's preclinical radiopharmaceuticals and ADC programs, which utilize their proprietary Accum® technology platform. Both programs aim to enhance cancer treatment efficacy by delivering radioactivity/drugs more precisely to cancer cells, potentially reducing dosing requirements and side effects for patients.

Defence Therapeutics has completed the first tranche of its non-brokered private placement, raising $775,000 through the sale of units at $0.50 each. Each unit comprises one common share and half a warrant, with each whole warrant exercisable at $1.00 per share within 24 months. The company paid $14,000 in finder's fees and issued 28,000 finder's warrants. The proceeds will support preclinical and clinical programs and working capital. All securities are subject to a four-month hold period.

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) announces corporate updates and financing plans. Key points include:

1. Sebastien Plouffe returns as CEO, replacing Kwin Grauer.

2. New board appointments: Dr. Philippe Lefrançois and Mr. Arnab De.

3. Dr. Moutih Rafei steps down from the board but remains CSO.

4. Joseph Meagher leaves the board but stays as CFO during transition to Arnab De.

5. 200,000 stock options granted to new directors at $0.60 per share.

6. Non-brokered private placement announced for up to $3 million at $0.50 per unit, with each unit including one common share and half a warrant.

7. Proceeds to be used for advancing preclinical and clinical programs, and working capital.